[go: up one dir, main page]

PT2718293T - Piridopirazinas substituídas como novos inibidores de syk - Google Patents

Piridopirazinas substituídas como novos inibidores de syk

Info

Publication number
PT2718293T
PT2718293T PT127971679T PT12797167T PT2718293T PT 2718293 T PT2718293 T PT 2718293T PT 127971679 T PT127971679 T PT 127971679T PT 12797167 T PT12797167 T PT 12797167T PT 2718293 T PT2718293 T PT 2718293T
Authority
PT
Portugal
Prior art keywords
syk inhibitors
novel syk
pyridopyrazines
substituted
substituted pyridopyrazines
Prior art date
Application number
PT127971679T
Other languages
English (en)
Inventor
Guo Su Wei
Deng Wei
Ji Jianguo
Original Assignee
Hutchison Medipharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47295336&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT2718293(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hutchison Medipharma Ltd filed Critical Hutchison Medipharma Ltd
Publication of PT2718293T publication Critical patent/PT2718293T/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541Non-condensed thiazines containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06Antianaemics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Otolaryngology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Conductive Materials (AREA)
PT127971679T 2011-06-08 2012-06-07 Piridopirazinas substituídas como novos inibidores de syk PT2718293T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2011/075431 WO2012167423A1 (en) 2011-06-08 2011-06-08 Substituted pyridopyrazines as novel syk inhibitors

Publications (1)

Publication Number Publication Date
PT2718293T true PT2718293T (pt) 2018-01-30

Family

ID=47295336

Family Applications (1)

Application Number Title Priority Date Filing Date
PT127971679T PT2718293T (pt) 2011-06-08 2012-06-07 Piridopirazinas substituídas como novos inibidores de syk

Country Status (32)

Country Link
US (2) US9434726B2 (pt)
EP (1) EP2718293B1 (pt)
JP (2) JP5940148B2 (pt)
KR (1) KR101571720B1 (pt)
CN (1) CN103596952B (pt)
AU (1) AU2012266941B2 (pt)
BR (1) BR112013031405B1 (pt)
CA (1) CA2836227C (pt)
CL (1) CL2013003512A1 (pt)
CY (1) CY1119953T1 (pt)
DK (1) DK2718293T3 (pt)
ES (1) ES2657549T3 (pt)
HR (1) HRP20180139T1 (pt)
HU (1) HUE037934T2 (pt)
IL (1) IL229410A (pt)
LT (1) LT2718293T (pt)
MX (1) MX355671B (pt)
MY (1) MY186599A (pt)
NO (1) NO2718293T3 (pt)
PE (1) PE20141167A1 (pt)
PH (1) PH12013502434A1 (pt)
PL (1) PL2718293T3 (pt)
PT (1) PT2718293T (pt)
RS (1) RS56901B1 (pt)
RU (1) RU2569635C9 (pt)
SG (1) SG195035A1 (pt)
SI (1) SI2718293T1 (pt)
SM (1) SMT201800057T1 (pt)
TW (1) TWI494311B (pt)
UA (1) UA111744C2 (pt)
WO (2) WO2012167423A1 (pt)
ZA (1) ZA201308947B (pt)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014507458A (ja) * 2011-03-11 2014-03-27 グラクソ グループ リミテッド Sykインヒビターとしてのピリド[3,4−B]ピラジン誘導体
WO2012167423A1 (en) * 2011-06-08 2012-12-13 Hutchison Medipharma Limited Substituted pyridopyrazines as novel syk inhibitors
WO2014028479A1 (en) 2012-08-13 2014-02-20 Envoy Therapeutics, Inc. Quinoxaline derivatives as gpr6 modulators
WO2014086032A1 (en) * 2012-12-07 2014-06-12 Hutchison Medipharma Limited Substituted pyridopyrazines as syk inhibitors
US10179783B2 (en) 2014-02-14 2019-01-15 Taketa Pharmaceutical Company Limited Tetrahydropyridopyrazines as modulators of GPR6
KR102431017B1 (ko) 2014-03-19 2022-08-11 베링거 인겔하임 인터내셔날 게엠베하 헤테로아릴 syk 억제제
AU2016280255A1 (en) 2015-06-18 2018-02-08 Cephalon, Inc. 1, 4-substituted piperidine derivatives
MX379846B (es) 2015-06-18 2025-03-11 89Bio Ltd Derivados de 4-bencil y 4-benzoil piperidina sustituidos.
CN105153211B (zh) * 2015-09-22 2017-02-01 上海晋鲁医药科技有限公司 一种合成1‑(N‑Boc‑4‑哌啶)‑4‑吡唑硼酸频哪醇酯的方法
CN110072865B (zh) 2017-02-08 2022-02-11 中国医药研究开发中心有限公司 吡咯并芳杂环类化合物及其制备方法和医药用途
AU2018302026B2 (en) * 2017-07-18 2022-04-07 Merck Patent Gmbh TLR7/8 antagonists and uses thereof
CN109422741A (zh) * 2017-08-22 2019-03-05 和记黄埔医药(上海)有限公司 化合物的盐及其晶型
JP2022526713A (ja) 2019-03-21 2022-05-26 オンクセオ がんの処置のための、キナーゼ阻害剤と組み合わせたDbait分子
KR20220098759A (ko) 2019-11-08 2022-07-12 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) 키나제 억제제에 대해 내성을 획득한 암의 치료 방법
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
KR20230043955A (ko) * 2020-07-23 2023-03-31 시토신랩 테라퓨틱스 코., 엘티디. 키나아제 억제 활성을 갖는 화합물
TW202313608A (zh) * 2021-06-04 2023-04-01 美商建南德克公司 2,8—二氮雜螺[4.5]癸烷化合物

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4022779A (en) * 1974-07-25 1977-05-10 E. R. Squibb & Sons, Inc. Amino derivatives of pyrido(3,4-b)pyrazine carboxylic acids and esters
US3989816A (en) 1975-06-19 1976-11-02 Nelson Research & Development Company Vehicle composition containing 1-substituted azacycloheptan-2-ones
US4444762A (en) 1980-04-04 1984-04-24 Nelson Research & Development Company Vehicle composition containing 1-substituted azacyclopentan-2-ones
JP2001302667A (ja) 2000-04-28 2001-10-31 Bayer Ag イミダゾピリミジン誘導体およびトリアゾロピリミジン誘導体
US20030158195A1 (en) * 2001-12-21 2003-08-21 Cywin Charles L. 1,6 naphthyridines useful as inhibitors of SYK kinase
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
JP4903997B2 (ja) * 2002-07-02 2012-03-28 サザン リサーチ インスティチュート FtsZの阻害剤およびそれらの用途
DE10323345A1 (de) * 2003-05-23 2004-12-16 Zentaris Gmbh Neue Pyridopyrazine und deren Verwendung als Kinase-Inhibitoren
DE602006010979D1 (de) 2005-01-19 2010-01-21 Rigel Pharmaceuticals Inc Prodrugs aus 2,4-pyrimidindiamin-verbindungen und ihre verwendungen
US8227455B2 (en) 2005-04-18 2012-07-24 Rigel Pharmaceuticals, Inc. Methods of treating cell proliferative disorders
RU2515944C9 (ru) * 2005-11-11 2014-07-20 Этерна Центарис ГмбХ ПРОИЗВОДНЫЕ ПИРИДОПИРАЗИНА, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ И СПОСОБ ЛЕЧЕНИЯ ИЛИ ПРОФИЛАКТИКИ ФИЗИОЛОГИЧЕСКИХ И/ИЛИ ПАТОФИЗИОЛОГИЧЕСКИХ СОСТОЯНИЙ ПОСРЕДСТВОМ ИНГИБИРОВАНИЯ ФЕРМЕНТОВ ERK, ERK1, ERK2, PI3K, PI3Kальфа, PI3Kбета, PI3Kгамма, PI3Kдельта, PI3K-С2альфа, PI3K-С2бета, PI3K-Vps34р (ВАРИАНТЫ)
TW200938542A (en) * 2008-02-01 2009-09-16 Irm Llc Compounds and compositions as kinase inhibitors
WO2010015520A1 (de) 2008-08-05 2010-02-11 Boehringer Ingelheim International Gmbh Substituierte naphthyridine und ihre verwendung als arzneimittel
US8722692B2 (en) * 2009-07-30 2014-05-13 Jianwei Che Compounds and compositions as Syk kinase inhibitors
PT2477987T (pt) * 2009-09-14 2018-03-13 Gilead Sciences Inc Moduladores de recetores do tipo toll
KR20120125267A (ko) 2010-01-29 2012-11-14 베링거 인겔하임 인터내셔날 게엠베하 치환된 나프티리딘 및 syk 키나제 억제제로서의 이의 용도
GB201007203D0 (en) 2010-04-29 2010-06-16 Glaxo Group Ltd Novel compounds
JP2014507458A (ja) * 2011-03-11 2014-03-27 グラクソ グループ リミテッド Sykインヒビターとしてのピリド[3,4−B]ピラジン誘導体
WO2012167423A1 (en) * 2011-06-08 2012-12-13 Hutchison Medipharma Limited Substituted pyridopyrazines as novel syk inhibitors
KR101986484B1 (ko) 2011-07-26 2019-06-10 베링거 인겔하임 인터내셔날 게엠베하 치환된 퀴놀린 및 이의 약제로서의 용도

Also Published As

Publication number Publication date
IL229410A (en) 2017-08-31
RU2013158996A (ru) 2015-07-20
US10052330B2 (en) 2018-08-21
EP2718293A1 (en) 2014-04-16
HK1190143A1 (zh) 2014-06-27
ES2657549T3 (es) 2018-03-05
NO2718293T3 (pt) 2018-03-24
SI2718293T1 (en) 2018-04-30
UA111744C2 (uk) 2016-06-10
PH12013502434A1 (en) 2014-01-13
HUE037934T2 (hu) 2018-09-28
CA2836227A1 (en) 2012-12-13
WO2012167733A1 (en) 2012-12-13
HRP20180139T1 (hr) 2018-05-18
RS56901B1 (sr) 2018-05-31
IL229410A0 (en) 2014-01-30
JP6175484B2 (ja) 2017-08-02
CN103596952B (zh) 2016-05-04
RU2569635C2 (ru) 2015-11-27
JP2016106100A (ja) 2016-06-16
BR112013031405B1 (pt) 2021-12-21
ZA201308947B (en) 2020-02-26
KR20140025559A (ko) 2014-03-04
CY1119953T1 (el) 2018-12-12
SG195035A1 (en) 2013-12-30
US20140121200A1 (en) 2014-05-01
JP5940148B2 (ja) 2016-06-29
AU2012266941A1 (en) 2013-11-28
LT2718293T (lt) 2018-02-12
CN103596952A (zh) 2014-02-19
BR112013031405A2 (pt) 2016-12-06
MX355671B (es) 2018-04-26
TWI494311B (zh) 2015-08-01
EP2718293B1 (en) 2017-10-25
KR101571720B1 (ko) 2015-11-25
MY186599A (en) 2021-07-29
MX2013014242A (es) 2014-04-14
RU2569635C9 (ru) 2016-07-10
US20160324864A1 (en) 2016-11-10
DK2718293T3 (da) 2018-01-29
EP2718293A4 (en) 2014-12-03
PE20141167A1 (es) 2014-09-03
CL2013003512A1 (es) 2014-07-18
CA2836227C (en) 2016-08-16
JP2014516059A (ja) 2014-07-07
WO2012167423A1 (en) 2012-12-13
US9434726B2 (en) 2016-09-06
TW201305160A (zh) 2013-02-01
NZ617765A (en) 2016-02-26
PL2718293T3 (pl) 2018-05-30
SMT201800057T1 (it) 2018-03-08
AU2012266941B2 (en) 2016-03-31

Similar Documents

Publication Publication Date Title
IL265897A (en) Transformed imidazopyridinyl – aminopyridine compounds
ZA201308947B (en) Substituted pyridopyrazines as novel syk inhibitors
GB201114103D0 (en) Novel compounds
GB201106799D0 (en) Novel compounds
GB201107325D0 (en) Novel compounds
GB201116641D0 (en) Novel compounds
GB201112607D0 (en) Novel compounds
IL239153A0 (en) Substitute pyridopyrazine as an inhibitor
GB201111704D0 (en) Novel compounds
EP2717694A4 (en) NEW COMPOUNDS
GB201122113D0 (en) Novel compounds
GB201122305D0 (en) Novel compound
GB201112987D0 (en) Novel compound
GB201104399D0 (en) Novel inhibitors
GB201109514D0 (en) Novel compounds
GB201103283D0 (en) Novel compounds
GB201111229D0 (en) Novel compounds
GB201111409D0 (en) Novel compounds
GB201111410D0 (en) Novel compounds
GB201111476D0 (en) Novel compounds
GB201106801D0 (en) Novel compounds
GB201111308D0 (en) Novel compounds
GB201113764D0 (en) Novel compounds
GB201113766D0 (en) Novel compounds
GB201104138D0 (en) Novel compounds